Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors

BACKGROUND: Poly(ADP-ribose) polymerase inhibitors (PARPi), coupled to a DNA damaging agent is a promising approach to treating triple negative breast cancer (TNBC). However, not all patients respond; we hypothesize that non-response in some patients may be due to insufficient drug penetration. As a...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Breast Cancer Res
Главные авторы: Bartelink, Imke H., Prideaux, Brendan, Krings, Gregor, Wilmes, Lisa, Lee, Pei Rong Evelyn, Bo, Pan, Hann, Byron, Coppé, Jean-Philippe, Heditsian, Diane, Swigart-Brown, Lamorna, Jones, Ella F., Magnitsky, Sergey, Keizer, Ron J, de Vries, Niels, Rosing, Hilde, Pawlowska, Nela, Thomas, Scott, Dhawan, Mallika, Aggarwal, Rahul, Munster, Pamela N., Esserman, Laura J., Ruan, Weiming, Wu, Alan H. B., Yee, Douglas, Dartois, Véronique, Savic, Radojka M., Wolf, Denise M., van ’t Veer, Laura
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2017
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5594551/
https://ncbi.nlm.nih.gov/pubmed/28893315
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-017-0896-4
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы